TrialsgrambetaRCTs are beautiful

2024 ESC Guidelines for the management of peripheral arterial and aortic diseases

This guideline cites 13 of the 199 landmark trials in our Cardiology register.

The 2024 ESC guideline merges peripheral arterial and aortic disease into one document, treating the arterial tree as a single organ. It covers antithrombotic therapy in peripheral artery disease, revascularisation in chronic limb-threatening ischaemia, aneurysm thresholds and surveillance, type B dissection and carotid disease. The register's landmark trials are grouped by vascular bed below.

Peripheral artery disease: antithrombotic therapy3

  • 2020VOYAGER PAD⁠Cardiology · Vascular · Antithrombotic therapyIn 6,564 patients with peripheral artery disease after lower-extremity revascularisation, rivaroxaban 2.5 mg twice daily plus aspirin reduced acute limb ischaemia, major amputation, myocardial infarction, ischaemic stroke or cardiovascular death compared with aspirin alone.HR 0.8595% CI 0.76-0.96Read →
  • 2017EUCLID⁠Cardiology · Vascular · Antithrombotic therapyIn 13,885 patients with symptomatic peripheral artery disease, ticagrelor monotherapy did not reduce cardiovascular death, myocardial infarction or ischaemic stroke compared with clopidogrel monotherapy.HR 1.0295% CI 0.92-1.13Read →
  • 2017COMPASS⁠Cardiology · Thrombosis · Chronic atherosclerosisIn 27,395 patients with stable coronary or peripheral artery disease, low-dose rivaroxaban plus aspirin reduced cardiovascular death, stroke or MI compared with aspirin alone.HR 0.76Read →

Chronic limb-threatening ischaemia: revascularisation2

  • 2023BASIL-2⁠Cardiology · Vascular · RevascularisationIn 345 patients with chronic limb-threatening ischaemia requiring infra-popliteal revascularisation, a vein-bypass-first strategy worsened amputation-free survival compared with a best-endovascular-treatment-first strategy.HR 1.3595% CI 1.02-1.80Read →
  • 2022BEST-CLI⁠Cardiology · Vascular · RevascularisationIn 1,830 patients with chronic limb-threatening ischaemia and infra-inguinal disease, surgical bypass reduced major adverse limb events or death compared with endovascular therapy, but only in those with an adequate single-segment great saphenous vein.Read →

Abdominal aortic aneurysm3

  • 2016EVAR-1⁠Cardiology · Vascular · Aortic aneurysmIn 1,252 patients with a large asymptomatic abdominal aortic aneurysm fit for either procedure, endovascular aneurysm repair gave an early survival benefit but inferior late all-cause and aneurysm-related mortality compared with open surgical repair.HR 1.1195% CI 0.97-1.27Read →
  • 2014IMPROVE⁠Cardiology · Vascular · Aortic aneurysmIn 613 patients with a clinical diagnosis of ruptured abdominal aortic aneurysm, an endovascular-first strategy did not reduce 30-day mortality compared with emergency open repair.OR 0.9295% CI 0.66-1.28Read →
  • 1998UK Small Aneurysm Trial Core⁠Cardiology · Vascular · Aortic aneurysmIn 1,090 patients aged 60–76 years with a symptomless abdominal aortic aneurysm of 4.0–5.5 cm, early elective open repair did not reduce long-term all-cause mortality compared with ultrasonographic surveillance.HR 0.9495% CI 0.75-1.17Read →

Type B aortic dissection1

  • 2013INSTEAD-XL⁠Cardiology · Vascular · Aortic dissectionIn 140 patients with stable uncomplicated type B aortic dissection, thoracic endovascular aortic repair added to optimal medical therapy reduced 5-year aorta-specific mortality and disease progression compared with optimal medical therapy alone.Read →

Carotid artery disease2

  • 2021ACST-2⁠Cardiology · Vascular · Carotid diseaseIn 3,625 asymptomatic patients with severe carotid stenosis, carotid artery stenting produced similar rates of procedural death or disabling stroke and 5-year non-procedural stroke compared with carotid endarterectomy.Read →
  • 2010CREST⁠Cardiology · Vascular · Carotid diseaseIn 2,502 patients with symptomatic or asymptomatic carotid stenosis, carotid-artery stenting did not differ from carotid endarterectomy for periprocedural stroke, myocardial infarction or death, or subsequent ipsilateral stroke at 4 years.HR 1.1195% CI 0.81-1.51Read →

Risk-factor modification2

  • 2017FOURIER⁠Cardiology · Lipids · PCSK9iIn 27,564 patients with ASCVD on statins, evolocumab reduced CV death, MI, stroke, hosp UA or revasc compared with placebo.HR 0.8595% CI 0.79-0.92Read →
  • 2000HOPE⁠Cardiology · Coronary · ACE inhibitorIn 9,297 high-risk patients with vascular disease or diabetes and preserved LV function, ramipril reduced MI, stroke, or cardiovascular death compared with placebo.RR 0.7895% CI 0.70-0.86Read →

Cited landmark trials not yet in the register6

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 1991NASCET / ECST

    Endarterectomy for symptomatic carotid stenosis — the trials that defined the stenosis thresholds.

  • 2004ACST-1

    Immediate endarterectomy versus deferral in asymptomatic carotid stenosis.

  • 2004DREAM

    Endovascular versus open repair of abdominal aortic aneurysm.

  • 2005BASIL-1

    Bypass versus angioplasty in severe limb ischaemia — the predecessor of BASIL-2.

  • 2010CASPAR

    Dual antiplatelet therapy after infra-inguinal bypass grafting.

  • 2012CLEVER

    Supervised exercise versus stenting for aortoiliac claudication.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.